Keros Ev To Sales vs Interest Coverage Analysis

KROS Stock

USD 14.65 0.08 0.55%

Keros Therapeutics financial indicator trend analysis is infinitely more than just investigating Keros Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Keros Therapeutics is a good investment. Please check the relationship between Keros Therapeutics Ev To Sales and its Interest Coverage accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Ev To Sales vs Interest Coverage

Ev To Sales vs Interest Coverage Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Keros Therapeutics Ev To Sales account and Interest Coverage. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Keros Therapeutics' Ev To Sales and Interest Coverage is -0.48. Overlapping area represents the amount of variation of Ev To Sales that can explain the historical movement of Interest Coverage in the same time period over historical financial statements of Keros Therapeutics, assuming nothing else is changed. The correlation between historical values of Keros Therapeutics' Ev To Sales and Interest Coverage is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Sales of Keros Therapeutics are associated (or correlated) with its Interest Coverage. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Coverage has no effect on the direction of Ev To Sales i.e., Keros Therapeutics' Ev To Sales and Interest Coverage go up and down completely randomly.

Correlation Coefficient

-0.48

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Interest Coverage

Most indicators from Keros Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Keros Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.Issuance Of Capital Stock is likely to gain to about 399.1 M in 2025, whereas Tax Provision is likely to drop slightly above 285 K in 2025.

	2024	2025 (projected)
Depreciation And Amortization	1.2M	927.8K
Interest Income	3.0M	3.1M

Depreciation And Amortization Interest Income

Keros Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.87	0.97	0.72	1.0	-0.81	0.84	0.92	0.74	-1.0	-0.97	0.85	1.0	0.91	0.88	0.94	0.73	1.0	0.8	0.91	0.73	0.85	0.96	0.92	0.43	0.99
Short Long Term Debt Total	0.87		0.95	0.79	0.86	-0.61	0.63	0.99	0.86	-0.85	-0.95	0.77	0.86	0.98	0.97	0.94	0.59	0.86	0.66	0.82	0.59	0.98	0.83	0.99	0.48	0.86
Other Current Liab	0.97	0.95		0.83	0.96	-0.76	0.8	0.98	0.84	-0.95	-0.99	0.88	0.96	0.98	0.94	0.99	0.69	0.96	0.75	0.92	0.69	0.93	0.94	0.98	0.58	0.96
Total Current Liabilities	0.72	0.79	0.83		0.7	-0.49	0.64	0.83	0.87	-0.72	-0.82	0.7	0.71	0.83	0.81	0.82	0.42	0.71	0.43	0.84	0.42	0.85	0.7	0.82	0.59	0.69
Total Stockholder Equity	1.0	0.86	0.96	0.7		-0.82	0.85	0.9	0.72	-1.0	-0.96	0.85	1.0	0.9	0.87	0.93	0.74	1.0	0.81	0.91	0.74	0.83	0.96	0.91	0.42	1.0
Other Liab	-0.81	-0.61	-0.76	-0.49	-0.82		-0.96	-0.68	-0.35	0.83	0.72	-0.93	-0.81	-0.69	-0.53	-0.76	-0.96	-0.81	-0.96	-0.88	-0.96	-0.53	-0.91	-0.67	-0.61	-0.82
Net Tangible Assets	0.84	0.63	0.8	0.64	0.85	-0.96		0.73	0.5	-0.87	-0.75	0.9	0.85	0.73	0.6	0.82	0.87	0.85	0.87	0.92	0.87	0.61	0.93	0.71	0.63	0.84
Property Plant And Equipment Net	0.92	0.99	0.98	0.83	0.9	-0.68	0.73		0.88	-0.9	-0.97	0.82	0.91	1.0	0.97	0.98	0.63	0.91	0.7	0.87	0.63	0.98	0.89	1.0	0.55	0.9
Current Deferred Revenue	0.74	0.86	0.84	0.87	0.72	-0.35	0.5	0.88		-0.71	-0.83	0.54	0.73	0.89	0.92	0.87	0.24	0.73	0.31	0.7	0.24	0.94	0.69	0.88	0.42	0.7
Net Debt	-1.0	-0.85	-0.95	-0.72	-1.0	0.83	-0.87	-0.9	-0.71		0.95	-0.86	-1.0	-0.9	-0.86	-0.93	-0.76	-1.0	-0.82	-0.92	-0.76	-0.82	-0.97	-0.9	-0.44	-0.99
Retained Earnings	-0.97	-0.95	-0.99	-0.82	-0.96	0.72	-0.75	-0.97	-0.83	0.95		-0.85	-0.96	-0.97	-0.95	-0.96	-0.67	-0.96	-0.74	-0.91	-0.67	-0.93	-0.91	-0.97	-0.48	-0.96
Accounts Payable	0.85	0.77	0.88	0.7	0.85	-0.93	0.9	0.82	0.54	-0.86	-0.85		0.84	0.82	0.68	0.86	0.9	0.84	0.91	0.94	0.9	0.7	0.92	0.8	0.75	0.84
Cash	1.0	0.86	0.96	0.71	1.0	-0.81	0.85	0.91	0.73	-1.0	-0.96	0.84		0.91	0.88	0.94	0.74	1.0	0.81	0.9	0.74	0.84	0.96	0.91	0.42	1.0
Non Current Assets Total	0.91	0.98	0.98	0.83	0.9	-0.69	0.73	1.0	0.89	-0.9	-0.97	0.82	0.91		0.97	0.99	0.63	0.91	0.7	0.88	0.63	0.98	0.9	1.0	0.56	0.9
Non Currrent Assets Other	0.88	0.97	0.94	0.81	0.87	-0.53	0.6	0.97	0.92	-0.86	-0.95	0.68	0.88	0.97		0.93	0.48	0.88	0.56	0.79	0.48	0.99	0.81	0.98	0.36	0.87
Other Assets	0.94	0.94	0.99	0.82	0.93	-0.76	0.82	0.98	0.87	-0.93	-0.96	0.86	0.94	0.99	0.93		0.67	0.94	0.73	0.92	0.67	0.94	0.95	0.98	0.59	0.93
Long Term Debt	0.73	0.59	0.69	0.42	0.74	-0.96	0.87	0.63	0.24	-0.76	-0.67	0.9	0.74	0.63	0.48	0.67		0.74	0.99	0.82	1.0	0.47	0.81	0.62	0.53	0.75
Cash And Short Term Investments	1.0	0.86	0.96	0.71	1.0	-0.81	0.85	0.91	0.73	-1.0	-0.96	0.84	1.0	0.91	0.88	0.94	0.74		0.81	0.9	0.74	0.84	0.96	0.91	0.42	1.0
Common Stock Total Equity	0.8	0.66	0.75	0.43	0.81	-0.96	0.87	0.7	0.31	-0.82	-0.74	0.91	0.81	0.7	0.56	0.73	0.99	0.81		0.83	0.99	0.55	0.86	0.69	0.51	0.82
Common Stock Shares Outstanding	0.91	0.82	0.92	0.84	0.91	-0.88	0.92	0.87	0.7	-0.92	-0.91	0.94	0.9	0.88	0.79	0.92	0.82	0.9	0.83		0.82	0.79	0.94	0.86	0.62	0.89
Long Term Debt Total	0.73	0.59	0.69	0.42	0.74	-0.96	0.87	0.63	0.24	-0.76	-0.67	0.9	0.74	0.63	0.48	0.67	1.0	0.74	0.99	0.82		0.47	0.81	0.62	0.53	0.75
Non Current Liabilities Total	0.85	0.98	0.93	0.85	0.83	-0.53	0.61	0.98	0.94	-0.82	-0.93	0.7	0.84	0.98	0.99	0.94	0.47	0.84	0.55	0.79	0.47		0.8	0.98	0.48	0.83
Capital Surpluse	0.96	0.83	0.94	0.7	0.96	-0.91	0.93	0.89	0.69	-0.97	-0.91	0.92	0.96	0.9	0.81	0.95	0.81	0.96	0.86	0.94	0.81	0.8		0.89	0.6	0.95
Capital Lease Obligations	0.92	0.99	0.98	0.82	0.91	-0.67	0.71	1.0	0.88	-0.9	-0.97	0.8	0.91	1.0	0.98	0.98	0.62	0.91	0.69	0.86	0.62	0.98	0.89		0.52	0.91
Other Current Assets	0.43	0.48	0.58	0.59	0.42	-0.61	0.63	0.55	0.42	-0.44	-0.48	0.75	0.42	0.56	0.36	0.59	0.53	0.42	0.51	0.62	0.53	0.48	0.6	0.52		0.44
Other Stockholder Equity	0.99	0.86	0.96	0.69	1.0	-0.82	0.84	0.9	0.7	-0.99	-0.96	0.84	1.0	0.9	0.87	0.93	0.75	1.0	0.82	0.89	0.75	0.83	0.95	0.91	0.44

Click cells to compare fundamentals

Keros Therapeutics Account Relationship Matchups

Keros Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	269.4M	255.3M	306.8M	370.0M	615.9M	646.7M
Short Long Term Debt Total	899K	1.1M	13.3M	14.4M	18.9M	19.8M
Other Current Liab	4.0M	6.4M	12.2M	17.9M	20.9M	21.9M
Total Current Liabilities	7.2M	11.8M	16.5M	24.4M	27.5M	16.2M
Total Stockholder Equity	261.7M	243.2M	277.4M	332.2M	571.6M	600.1M
Net Tangible Assets	(19.4M)	261.7M	243.2M	277.4M	319.0M	166.3M
Property Plant And Equipment Net	1.6M	2.4M	17.6M	19.5M	23.5M	24.7M
Current Deferred Revenue	1.9M	4.4M	7.1M	17.3M	19.8M	20.8M
Net Debt	(265.0M)	(228.9M)	(265.8M)	(316.7M)	(541.1M)	(514.0M)
Retained Earnings	(65.0M)	(123.8M)	(228.4M)	(381.4M)	(568.8M)	(540.3M)
Accounts Payable	2.1M	3.6M	3.3M	5.5M	4.6M	3.4M
Cash	265.9M	230.0M	279.0M	331.1M	559.9M	587.9M
Non Current Assets Total	1.7M	3.8M	21.0M	22.7M	27.0M	28.3M
Other Assets	115K	993K	1.4M	3.4M	4.0M	4.2M
Cash And Short Term Investments	265.9M	230.0M	279.0M	331.1M	559.9M	587.9M
Common Stock Shares Outstanding	15.5M	23.3M	25.2M	29.4M	37.4M	23.4M
Liabilities And Stockholders Equity	269.4M	255.3M	306.8M	370.0M	615.9M	646.7M
Non Current Liabilities Total	538K	231K	12.8M	13.4M	16.9M	17.7M
Capital Surpluse	203K	326.7M	366.9M	505.9M	581.7M	610.8M
Capital Lease Obligations	899K	1.1M	13.3M	14.4M	18.9M	19.8M
Other Current Assets	1.6M	3.2M	5.9M	15.1M	1.5M	1.4M
Other Stockholder Equity	596.2M	366.9M	505.9M	713.6M	1.1B	1.2B
Total Liab	7.7M	12.1M	29.4M	37.8M	44.3M	23.8M
Net Invested Capital	261.7M	243.2M	277.4M	332.2M	571.6M	600.1M
Property Plant And Equipment Gross	1.6M	2.4M	17.6M	21.2M	26.4M	27.8M
Total Current Assets	267.7M	251.4M	285.8M	347.3M	588.9M	618.3M
Non Current Liabilities Other	119K	62K	231K	12.8M	14.7M	15.5M
Net Working Capital	260.5M	239.6M	269.2M	322.9M	561.4M	589.5M
Short Term Debt	846K	1.7M	910K	1.0M	2.0M	1.1M
Property Plant Equipment	1.9M	1.6M	1.3M	2.0M	2.3M	1.8M
Net Receivables	216K	18M	841K	1.1M	4.5M	4.7M
Inventory	1.5M	3.1M	(841K)	14.1M	16.2M	17.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC